Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| BATS Europe | GBP | Delayed | ||
| BATS Europe | SEK | Delayed | ||
| NASDAQ | USD | Real-time | ||
| OTC Markets | USD | Delayed | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
AstraZeneca AZNUK:AZN said Thursday that the Food and Drug Administration is no longer allowing healthcare providers to prescribe Evusheld, a therapy authorized for pre-exposure...
By Scott Kanowsky Investing.com -- AstraZeneca PLC (LON:AZN) has agreed to acquire U.S. biotech CinCor Pharma Inc (NASDAQ:CINC) in a deal worth as much as $1.8 billion, as the...
By Peter Nurse Investing.com - European stock markets edged higher Monday, with sentiment boosted by China’s decision to fully reopen its borders as well as stronger-than-expected...
Shares in UK-headquartered AstraZeneca are back under heavy selling pressure on Monday as the stock extends recent losses.
Enhertu is an antibody-drug conjugate, a type of therapy designed to do minimal damage to healthy, non-cancerous cells. Wall Street analysts believe that Enhertu has the potential...
WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which...
AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Buy | Sell | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.005 | 0.005 | 0.005 | -0.0050 | -50.00% | 17.00K | TSXV | |||
| 0.005 | 0.005 | 0.005 | -0.0050 | -50.00% | 250.00K | TSXV | |||
| 0.01 | 0.01 | 0.005 | +0.0050 | +100.00% | 121.82K | TSXV | |||
| 0.01 | 0.01 | 0.01 | +0.005 | +100.00% | 1.00K | CSE | |||
| 0.005 | 0.005 | 0.005 | 0.00 | 0.00% | 0.00 | TSXV | |||
| 0.01 | 0.01 | 0.005 | +0.005 | +100.00% | 169.00K | CSE | |||
| 0.005 | 0.01 | 0.005 | -0.0050 | -50.00% | 7.90K | TSXV | |||
| 0.005 | 0.005 | 0.005 | -0.0100 | -66.67% | 100.00K | TSXV | |||
| 3.93 | 4.24 | 3.88 | -0.260 | -6.21% | 4.24M | Toronto | |||
| 17.89 | 17.89 | 17.76 | +0.02 | +0.11% | 9.39K | Toronto | |||
| 0.05 | 0.05 | 0.05 | 0.00 | 0.00% | 5.00K | TSXV | |||
| 0.26 | 0.27 | 0.25 | -0.0050 | -1.89% | 106.05K | TSXV | |||
| 0.0225 | 0.025 | 0.02 | +0.0025 | +12.50% | 170.35K | Toronto | |||
| 27.00 | 28.50 | 27.00 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 0.06 | 0.06 | 0.06 | 0.00 | 0.00% | 49.00K | TSXV |